Physician profile
Christopher Bernadas
NPI 1649632050
$6,319.32
in general payments reported to CMS, 2019-2025
18 companies · $787 in 2025
The $787 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $563 · 2021: $1,088 · 2022: $1,383 · 2023: $1,218 · 2024: $876 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $2,379.94 | 2020-2025 | Nuplazid |
| Abbvie INC. | $604.12 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $520.00 | 2020-2025 | Caplyta |
| Alkermes, INC. | $445.32 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $418.49 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $415.16 | 2020-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $390.14 | 2019-2025 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $383.19 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $165.70 | 2022-2025 | Invega Sustenna |
| Avanir Pharmaceuticals, INC. | $158.68 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.51 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $112.93 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $68.79 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.30 | 2024-2025 | Cobenfy |
| Allergan, INC. | $24.09 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.14 | 2022 | |
| Axsome Therapeutics, INC. | $17.92 | 2023 | Auvelity |
| Alpha Cognition USA, INC. | $13.90 | 2025 | Zunveyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bernadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.